Lrrk2 pathogenic substitutions in Parkinson's disease

被引:198
作者
Mata, IF
Kachergus, JM
Taylor, JP
Lincoln, S
Aasly, J
Lynch, T
Hulihan, MM
Cobb, SA
Wu, RM
Lu, CS
Lahoz, C
Wszolek, ZK
Farrer, MJ
机构
[1] Mayo Clin, Dept Neurosci, Mol Genet Lab & Core, Morris K Udall Parkinsons Dis,Res Ctr Excellence, Jacksonville, FL 32224 USA
[2] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
[3] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA
[4] St Olavs Hosp, Dept Neurol, Trondheim, Norway
[5] Mater Misericordiae Univ Hosp, Dept Neurol, Dublin, Ireland
[6] Conway Inst Biomol & Biomed Res, Dublin, Ireland
[7] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Neurol, Taipei 10018, Taiwan
[8] Chang Gung Mem Hosp, Dept Neurol, Tao Yuan, Taiwan
[9] Hosp Univ Cent Asturias, Serv Neurol, Oviedo, Spain
关键词
LRRK2; kinase; idiopathic Parkinson's disease; mutation; polymorphism;
D O I
10.1007/s10048-005-0005-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein. To identify novel LRRK2 mutations, we have sequenced 100 affected probands with family history of parkinsonism. Semiquantitative analysis was also performed in all probands to identify LRRK2 genomic multiplication or deletion. In these kindreds, referred from movement disorder clinics in many parts of Europe, Asia, and North America, parkinsonism segregates as an autosomal dominant trait. All 51 exons of the LRRK2 gene were analyzed and the frequency of all novel sequence variants was assessed within controls. The segregation of mutations with disease has been examined in larger, multiplex families. Our study identified 26 coding variants, including 15 nonsynonymous amino acid substitutions of which three affect the same codon (R1441C, R1441G, and R1441H). Seven of these coding changes seem to be pathogenic, as they segregate with disease and were not identified within controls. No multiplications or deletions were identified.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 23 条
  • [1] Multiple regions contribute to membrane targeting of Rab GTPases
    Ali, BR
    Wasmeier, C
    Lamoreux, L
    Strom, M
    Seabra, MC
    [J]. JOURNAL OF CELL SCIENCE, 2004, 117 (26) : 6401 - 6412
  • [2] Roc, a Ras/GTPase domain in complex proteins
    Bosgraaf, L
    Van Haastert, PJM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1643 (1-3): : 5 - 10
  • [3] Stages in the development of Parkinson's disease-related pathology
    Braak, H
    Ghebremedhin, E
    Rüb, U
    Bratzke, H
    Del Tredici, K
    [J]. CELL AND TISSUE RESEARCH, 2004, 318 (01) : 121 - 134
  • [4] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [5] Di Fonzo A, 2005, LANCET, V365, P412
  • [6] The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?
    Di Monte, DA
    [J]. LANCET NEUROLOGY, 2003, 2 (09) : 531 - 538
  • [7] Description of Parkinson's disease as a clinical syndrome
    Fahn, S
    [J]. PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 : 1 - 14
  • [8] An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family
    Funayama, M
    Hasegawa, K
    Ohta, E
    Kawashima, N
    Komiyama, M
    Kowa, H
    Tsuji, S
    Obata, F
    [J]. ANNALS OF NEUROLOGY, 2005, 57 (06) : 918 - 921
  • [9] A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1
    Funayama, M
    Hasegawa, K
    Kowa, H
    Saito, M
    Tsuji, S
    Obata, F
    [J]. ANNALS OF NEUROLOGY, 2002, 51 (03) : 296 - 301
  • [10] Diagnostic criteria for Parkinson disease
    Gelb, DJ
    Oliver, E
    Gilman, S
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (01) : 33 - 39